LeMaitre Vascular (NASDAQ:LMAT) Stock Price Expected to Rise, Citizens Jmp Analyst Says

Key Points

• Citizens Jmp raised its price target on LeMaitre Vascular from $118 to $127 and kept a "market outperform" rating, implying roughly a 19.8% upside from the prior close.
• Q1 results and guidance: the company reported $0.68 EPS (vs. $0.66 consensus) with revenue up 11.1% y/y and management raised Q2 guidance to $0.79–$0.84 and FY26 to $2.93–$3.08 EPS.
• Insider selling and ownership: insiders sold about 215,438 shares (~$23.06M) in the last 90 days, while insiders still own 7.4% and institutional investors hold 84.64% of the stock.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) had its target price raised by stock analysts at Citizens Jmp from $118.00 to $127.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage currently has a "market outperform" rating on the medical instruments supplier's stock. Citizens Jmp's price objective indicates a potential upside of 19.84% from the stock's previous close.

Several other equities research analysts have also issued reports on the stock. Freedom Capital raised shares of LeMaitre Vascular to a "hold" rating in a report on Tuesday, March 31st. Wall Street Zen raised shares of LeMaitre Vascular from a "hold" rating to a "buy" rating in a report on Saturday, February 21st. Wells Fargo & Company lifted their price target on shares of LeMaitre Vascular from $94.00 to $104.00 and gave the company an "equal weight" rating in a report on Wednesday. Weiss Ratings raised shares of LeMaitre Vascular from a "hold (c+)" rating to a "buy (b-)" rating in a report on Tuesday, March 10th. Finally, Roth Mkm reaffirmed a "buy" rating and set a $117.00 price target (up from $108.00) on shares of LeMaitre Vascular in a report on Thursday, February 26th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $109.60.

LeMaitre Vascular Price Performance

LMAT stock traded down $6.03 during mid-day trading on Wednesday, hitting $105.98. The stock had a trading volume of 68,549 shares, compared to its average volume of 202,315. The company has a current ratio of 12.89, a quick ratio of 10.95 and a debt-to-equity ratio of 0.43. LeMaitre Vascular has a 52 week low of $78.35 and a 52 week high of $118.01. The firm has a market capitalization of $2.42 billion, a P/E ratio of 41.65, a P/E/G ratio of 3.21 and a beta of 0.60. The firm has a fifty day simple moving average of $109.28 and a 200 day simple moving average of $94.17.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 EPS for the quarter, beating the consensus estimate of $0.66 by $0.02. LeMaitre Vascular had a net margin of 23.13% and a return on equity of 14.72%. The firm had revenue of $66.55 million for the quarter, compared to analyst estimates of $66.67 million. During the same period last year, the firm earned $0.48 EPS. The business's quarterly revenue was up 11.1% compared to the same quarter last year. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. As a group, research analysts forecast that LeMaitre Vascular will post 2.89 EPS for the current year.

Insider Buying and Selling

In related news, insider Trent G. Kamke sold 1,044 shares of LeMaitre Vascular stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $110.29, for a total transaction of $115,142.76. Following the sale, the insider directly owned 6,677 shares in the company, valued at $736,406.33. This trade represents a 13.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director David B. Roberts sold 8,464 shares of LeMaitre Vascular stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $106.80, for a total transaction of $903,955.20. Following the sale, the director owned 17,979 shares in the company, valued at approximately $1,920,157.20. This represents a 32.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 215,438 shares of company stock worth $23,062,911 in the last ninety days. Company insiders own 7.40% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Bessemer Group Inc. lifted its position in shares of LeMaitre Vascular by 292.3% in the 1st quarter. Bessemer Group Inc. now owns 171,838 shares of the medical instruments supplier's stock worth $18,759,000 after purchasing an additional 128,033 shares during the period. Illumine Investment Management LLC lifted its position in shares of LeMaitre Vascular by 3.8% in the 1st quarter. Illumine Investment Management LLC now owns 14,874 shares of the medical instruments supplier's stock worth $1,624,000 after purchasing an additional 538 shares during the period. Principal Financial Group Inc. lifted its position in shares of LeMaitre Vascular by 4.3% in the 1st quarter. Principal Financial Group Inc. now owns 117,840 shares of the medical instruments supplier's stock worth $12,865,000 after purchasing an additional 4,874 shares during the period. Hardy Reed LLC acquired a new position in shares of LeMaitre Vascular in the 1st quarter worth approximately $254,000. Finally, Sound Income Strategies LLC lifted its position in shares of LeMaitre Vascular by 425.6% in the 1st quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier's stock worth $25,000 after purchasing an additional 183 shares during the period. Institutional investors and hedge funds own 84.64% of the company's stock.

LeMaitre Vascular News Roundup

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Q1 EPS topped expectations: $0.68 vs. consensus $0.66, up from $0.48 a year ago — supports earnings momentum. LeMaitre Vascular (LMAT) Tops Q1 Earnings Estimates
• Positive Sentiment: Management raised guidance: Q2 EPS guided to $0.790–$0.840 (above consensus ~$0.760) and FY26 EPS to $2.930–$3.080 (vs. consensus ~2.90) — indicates confidence in continuing earnings growth. LeMaitre Q1 2026 Financial Results (press release / guidance)
• Positive Sentiment: Board declared a quarterly cash dividend of $0.25/share (ex-dividend May 21) — modest income support, though yield (~0.9%) is small. LeMaitre Q1 2026 Financial Results
• Neutral Sentiment: Revenue grew 11.1% year-over-year, showing solid top-line growth, but was essentially in line with expectations ($66.55M vs. $66.67M consensus). LeMaitre NASDAQ: LMAT Posts Q1 CY2026 Sales In Line With Estimates
• Neutral Sentiment: Full earnings release and conference call materials available for deeper review (transcript posted). Useful for investors wanting color on procedure volumes, margin drivers, and buyback/dividend plans. LeMaitre Vascular, Inc. (LMAT) Q1 2026 Earnings Call Transcript
• Negative Sentiment: Revenue slightly missed consensus by a small margin (about $0.12M), and the sales figure was effectively “in line” not a clear beat — reduces upside surprise potential. LeMaitre Q1 earnings report (MarketBeat)

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company's offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre's product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.